GLP-1 receptor agonists and SGLT2 inhibitors in cardiovascular practice: insights from a national survey of French cardiologists.

Sorbonne university, ACTION Study Group, INSERM UMRS_1166, Cardiology Institute, Pitié Salpêtrière hospital (AP-HP) Paris, 75013 Paris, France., France

Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy., Italy

Universidade de São Paulo Faculdade de Medicina: São Paulo, SP, BR, Brazil

Department of Cardiology, CMC Ambroise Paré, Neuilly-sur-Seine, France., France

University of Florida: Gainesville, Florida, US, United States

Collège National des Cardiologues Français, 13 rue Niepce, 75014 Paris, France, France

Jesselson Integrated Heart Center, Shaare Zedek Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel, Israel

Policlinico Casilino, Italy

Department of Clinical and Experimental Medicine, University of Messina, Italy, Italy

Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland, Poland

Department of Cardiology, Assistance Publique-Hôpitaux de Paris, Henri Mondor University Hospital, Créteil, France, France

Submission date: 2026-05-27

Final revision date: 2026-07-19

Acceptance date: 2026-07-26

Online publication date: 2026-07-26

Corresponding author

Pierre François Sabouret

Sorbonne university, ACTION Study Group, INSERM UMRS_1166, Cardiology Institute, Pitié Salpêtrière hospital (AP-HP) Paris, 75013 Paris, France., France

DOI: https://doi.org/10.5114/aoms/226415

Article (PDF)

References (13)

KEYWORDS

diabetes

atherosclerosis

cardiovascular disease

prescription

SGLT2 inhibitors

GLP1 receptor agonists

TOPICS

ABSTRACT

Introduction:
Not applicable.

Material and methods:
Not applicable.

Results:
Not applicable.

Conclusions:
Not applicable.

REFERENCES (13)

. Marx N, Federici M, Schutt K, Muller-Wieland D, Ajjan RA, Antunes MJ, Christodorescu RM, Crawford C, Di Angelantonio E, Eliasson B, Espinola-Klein C, Fauchier L, Halle M, Herrington WG, Kautzky-Willer A, Lambrinou E, Lesiak M, Lettino M, McGuire DK, Mullens W, Rocca B, Sattar N, Group ESCSD. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44:4043-4140.

Google Scholar

. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Das SR, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Kosiborod M, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46:S158-S190.

Google Scholar

. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45:2753-2786.

Google Scholar

. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Munoz D, Smith SC Jr., Virani SS, Williams KA Sr., Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596-e646.

Google Scholar

. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr., Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139:e1082-e1143.

Google Scholar

. Bernardi M, Spadafora L, Galli M, Biondi-Zoccai G, Sabouret P. Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients? Arch Med Sci. 2023;19:528-531.

Google Scholar

. Eckel RH, Blaha MJ. Cardiometabolic Medicine: A Call for a New Subspeciality Training Track in Internal Medicine. Am J Med. 2019;132:788-790.

Google Scholar

. Saxon DR, Reiter-Brennan C, Blaha MJ, Eckel RH. Cardiometabolic Medicine: Development of a New Subspecialty. J Clin Endocrinol Metab. 2020;105.

Google Scholar

. Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, Coresh J, Mathew RO, Baker-Smith CM, Carnethon MR, Despres JP, Ho JE, Joseph JJ, Kernan WN, Khera A, Kosiborod MN, Lekavich CL, Lewis EF, Lo KB, Ozkan B, Palaniappan LP, Patel SS, Pencina MJ, Powell-Wiley TM, Sperling LS, Virani SS, Wright JT, Rajgopal Singh R, Elkind MSV. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148:1606-1635.

Google Scholar

10.

. Katsiki N, Kolovou G, Vrablik M. Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease. Curr Cardiol Rep. 2025;27:19.

Google Scholar

11.

. Katsiki N, Kolovou G, Melidonis A, Banach M. The Cardiac-Kidney-Liver (CKL) syndrome: the “real entity” of type 2 diabetes mellitus. Arch Med Sci. 2024;20:207-215.

Google Scholar

12.

. Muzurović E, Katsiki N, Volčanšek Š, Plescia F, Rizzo M, Mantzoros CS. Emerging incretin- and multi-agonist-based treatments: the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond. Metabolism. 2026;177:156494.

Google Scholar

13.

. American Diabetes Association Professional Practice Committee. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S246-S260.

Google Scholar

Submit your paper

eISSN:	1896-9151
ISSN:	1734-1922